Projektin tiedot

Description

The blood-brain barrier (BBB) is a major obstacle in treating diseases of the central nervous system (CNS) such as Parkinson’s, Alzheimer’s, schizophrenia and brain cancer, affecting 180 million Europeans with less than 5% of current candidate drugs effectively reaching the brain. NAP4DIVE strives to revolutionize the traditionally expensive and inefficient drug development for these diseases by establishing advanced non-animal alternatives for testing and predicting nanoparticle (NP)-based drug delivery across the human BBB. This approach aligns with EU and global initiatives to reduce animal testing and advance human-based biomedical research models.
AkronyymiNAP4DIVE
TilaKäynnissä
Todellinen alku/loppupvm01/01/2531/12/28

Yhteistyöpartnerit

  • Åbo Akademi (johto)
  • Finnadvance Oy
  • AstraZeneca Ab
  • Göteborgin yliopisto
  • Chalmersin teknillinen korkeakoulu
  • Microfluidics Innovation Center
  • Delft University of Technology
  • HansaBioMed Life Sciences Ou
  • Betthera s.r.o.
  • AMIRES s.r.o.
  • Eindhoven University of Technology

Rahoitus

  • European Commission